The Technical Analyst
Global X Genomics & [GNOM]
Exchange: NASDAQ
Global X Genomics & Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.85% $9.94
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 102.74 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | N/A |
| SharesOutstanding: | 10.34 mill |
| Avg Daily Volume: | 0.0748 mill |
| RATING 2022-03-25 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 14.70 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 17.27 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 9.68 - 10.20 ( +/- 2.65%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2013-03-14 | Ovp Venture Partners Vi Lp | Sell | 1 424 629 | Common Stock, par value $0.001 |
| 2013-03-18 | Ovp Venture Partners Vi Lp | Sell | 52 735 | Warrant to purchase Common Stock |
| 2013-03-14 | Wall Robert T | Sell | 51 666 | Common Stock, par value $0.001 |
| 2013-03-18 | Wall Robert T | Sell | 8 000 | Stock Option (right to buy) |
| 2013-03-18 | Wall Robert T | Sell | 4 000 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 0.00 |
| Last 100 transactions |
| Buy: 9 325 308 | Sell: 6 899 558 |
Forecast:
16:00 - $9.94
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $9.94
Forecast 2: 16:00 - $9.94
Forecast 3: 16:00 - $9.94
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $9.94 (-0.85% ) |
| Volume | 0.189 mill |
| Avg. Vol. | 0.0748 mill |
| % of Avg. Vol | 252.97 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GNOM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GNOM
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.
Last 10 Buy Signals
Latest News
2024-03-22 15:49:45 - Seeking Alpha
GNOM: Genomics Still Waiting For Its 'ChatGPT' Moment
GNMO invests across companies benefiting from advancements in the field of genomics within biotechnology. The fund's historical performance has been poor amid volatile stock prices for underlying holdings. Genomics may be the future, but still missing a blockbuster application to drive a wave of bullish momentum into the segment.
2024-03-21 16:19:51 - InvestorPlace
3 Stocks That Could Be the Next Big Thing in Gene Editing
Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.
2024-02-13 06:05:00 - InvestorPlace
3 Gene Editing Stocks With Unprecedented Surge Potential
Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions.
2024-01-31 12:28:10 - InvestorPlace
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.
2023-10-18 11:05:28 - InvestorPlace
3 Gene Editing Stocks to Generate Super-Charged Gains
Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroducing them, we could help treat sickle-cell anemia, cancers, blood disorders, blindness, cystic fibrosis, and even muscular dystrophy if all goes according to plan.
2023-08-14 08:15:00 - Seeking Alpha
Healthcare Dashboard For August And Focus On GNOM
This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value and quality scores. Healthcare equipment is the most overvalued subsector.
2023-05-28 04:02:14 - Seeking Alpha
GNOM: A Genomics ETF That Will Have Its Day, Even If Not Right Now
GNOM is a $200 million ETF that invests in a forward-looking set of innovative businesses focused on the genomics industry. This is a long-term growth area, but it will need to get more profitable to get more popular. That could take a little while.
2023-03-25 09:17:25 - InvestorPlace
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
CRISPR could revolutionize the way we treat thousands of diseases. Currently, there are about 7,000 caused by genetic disorders, which occur when a mutation affects your genes, or when you have the wrong amount of genetic material, as noted by the Cleveland Clinic.
2023-03-15 11:31:39 - InvestorPlace
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.
2023-01-24 09:02:08 - Zacks Investment Research
Will 2023 be the Year of Cathie Wood ETFs?
Cathie Wood, famous for the success of Ark Investment???s winning products, had faced a miserable fate in 2022.